Exact Sciences
S01E103 : PRECISION ONCO 3/3 : EXACT SCIENCES
04 October 2026. The ledger bleeds open on Exact Sciences. We dissect the $21 billion Abbott buyout, the liquid biopsy mirage, and the grim reality of Medicare gatekeepers.
Theme: Precision Onco
DETECTION LENS: The "Early Detection" market, liquid biopsy sensitivity, and reimbursement hurdles.
Exact Sciences
NOTES: Exact Sciences: The $21B Blood Mirage: Exact Sciences' Oncology Fleecing
Exposing the Adjusted EBITDA double-speak behind Exact Sciences' precision oncology pipeline and the structural trap of the early cancer detection market.
Exact Sciences
AUDIT: Exact Sciences: Blood and Bureaucracy: The Oncology Mirage
An objective analysis of Exact Sciences' $21 billion acquisition by Abbott Laboratories, examining the gap between precision oncology revenue and liquid biopsy reimbursement hurdles.
Cassandra Protocol
S01E100 : PRECISION ONCO 2/3 : NATERA
02 October 2026. The Q4 archives open on Natera and the brittle architecture of precision oncology. We dissect the miracle of early cancer detection against the crumbling infrastructure of healthcare reimbursement. Step into the cold and press play.
Natera
NOTES: Natera: Selling Ghosts: Natera's Precision Oncology Mirage
Natera is selling a subscription model for survival, but the financial architecture is bleeding. An analysis of the reimbursement void in precision oncology and the corporate mirage of standard-of-care diagnostics.
Natera
AUDIT: Natera: The Blood Ledger: Precision Oncology’s Blind Spot
An audit of Natera's Signatera assay and the structural realities of precision oncology. Examining the clinical infrastructure of molecular residual disease detection versus the limitations of healthcare reimbursement models.
Medical Technology
S01E97 : PRECISION ONCO 1/3 : GUARDANT HEALTH
On 30 September 2026, the Cassandra Archive pulls the ledger on Guardant Health. We explore the silent gap between the promised medical miracles of precision oncology and a corporate casino built on human plasma.
Biotech Finance
NOTES: Guardant Health: Blood Money: Guardant's Liquid Biopsy Illusion
Marcus exposes the financial anatomy of Guardant Health's liquid biopsy engine, breaking down the catastrophic cash burn and non-GAAP illusions masking the true unit economics of early cancer screening.
Guardant Health
AUDIT: Guardant Health: The Blood Ledger: Scaling the Illusion of Precision
Katie dissects Guardant Health's aggressive market penetration strategy, explaining how massive volume surges in the Shield liquid biopsy test secure institutional adoption despite underlying margin friction.